Chemed Corp stock hits 52-week low at 500.0 USD

Chemed Corp (NYSE:CHE) stock has reached a 52-week low, touching a price of 500.0 USD. This milestone comes amidst a broader market fluctuation, though the company maintains a strong "GREAT" financial health score according to InvestingPro analysis. The stock typically demonstrates low price volatility, with management actively buying back shares. Over the past year, Chemed Corp has experienced a modest increase, with a 1-year change of 3.67%. The company has maintained dividend payments for 55 consecutive years, demonstrating consistent shareholder returns. While analysts have set price targets between $640 and $650, suggesting potential upside, the current dip to its 52-week low indicates challenges that the company may be facing in maintaining its stock value. Investors will be watching closely to see how Chemed Corp navigates these market conditions. For deeper insights and additional ProTips about Chemed Corp, including its comprehensive Fair Value analysis, visit InvestingPro.

In other recent news, Chemed Corporation reported its first-quarter 2025 financial results, surpassing analysts’ expectations with an earnings per share (EPS) of $5.63, compared to the forecasted $5.51. The company’s revenue reached $646.9 million, exceeding the anticipated $636.8 million. RBC Capital Markets responded by raising Chemed’s stock price target from $667 to $674, citing a robust first-quarter earnings report and a positive outlook for the Roto-Rooter business. BofA Securities maintained a Buy rating on Chemed, with a price target of $708, after discussions with the company’s leadership about strategies for managing Medicare cap challenges.

Chemed’s annual stockholders’ meeting also resulted in the election of all nominated directors and approval of the 2025 Stock Incentive Plan. The appointment of PricewaterhouseCoopers LLP as independent accountants was ratified, and the executive compensation program received approval on a non-binding basis. Analysts have noted Chemed’s proactive steps in handling Medicare cap issues, with BofA Securities highlighting the company’s confidence in navigating these challenges without impacting growth prospects.

The company’s Vitas Healthcare segment reported a 15.1% increase in net revenue year-over-year, while the Roto-Rooter division saw a modest 3.1% growth in gross branch revenue. Despite these positive developments, Chemed’s stock experienced a decline in after-hours trading, reflecting broader market volatility and sector-specific challenges. Investors and analysts will likely continue to monitor Chemed’s strategic management and financial performance closely.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.